MedTrace Logo

Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism

NCT06183944 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2026-04-13

No results posted yet for this study

Summary

The aim will be to identify clinically relevant phenotypes in patients with acute pulmonary embolism. Hierarchical clustering methods combined with unsupervised learning (machine learning) will be used to obtain groups of patients who are homogeneous at diagnosis. Evaluating their prognosis at 6 months (recurrence or chronic thromboembolic pulmonary hypertension), account the first 3 months of anticoagulant treatment, would provide an aid to medical decision-making.

This research will include a retrospective and a prospective parts. The retrospective part will include patients who have been admitted to CHITS for acute pulmonary embolism since 2019. For the prospective part, it is planned to include patients with same characteristics over the years 2024 and 2025. More than 2,500 patients are expected to be included.

This research will have no impact on current patient care. Data from consultations and various examinations carried out as part of care will be collected for six months post-diagnosis in order to meet the research objectives.

Conditions

Interventions

OTHER

Hierarchical clustering methods

Hierarchical clustering methods will be used to form homogeneous groups of patients based on their data at diagnosis: presence or absence of symptoms, clinical and biological data, and presence or absence of favouring factors. Patient evolution at 6 months can fall into categories: stable, aggravation or progress, which are determined by events such as recurrence, hemorrhage, functional sequelae or death.

Sponsors & Collaborators

  • Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

    lead OTHER

Principal Investigators

  • Jean-Noël POGGI, MD · Centre Hospitalier Intercommunal Toulon La Seyne sur Mer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-11
Primary Completion
2026-07-01
Completion
2026-07-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06183944 on ClinicalTrials.gov